Effects of haloperidol on antioxidant defense system enzymes in schizophrenia

Journal of Psychiatric Research

Volumn 32, Issue 6, 1998, Pages 385-391

  Yao, Jeffrey K ^a,b   Reddy, Ravinder ^b   McElhinny, Luke G ^a   Van Kammen, Daniel P ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; CATALASE; COTININE; ERYTHROCYTE ENZYME; FREE RADICAL; GLUTATHIONE PEROXIDASE; HALOPERIDOL; NEUROLEPTIC AGENT; SUPEROXIDE DISMUTASE;

ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; CELL METABOLISM; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME DEFECT; ERYTHROCYTE; HUMAN; MALE; PRIORITY JOURNAL; RELAPSE; SCHIZOPHRENIA; SMOKING; SYMPTOM;

EID: 0032170923     PISSN: 00223956     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-3956(98)00028-4     Document Type: Article

References (37)

1. Abdalla DSP, Manteiro HP, Olivera JAC, Bechara CH. Activities of superoxide dismutase and glutathione peroxidase in schizophrenic and manic depressive patients. Clin Chem 1986;32:805-807.
2. Aebi H. Catalase in vitro. Methods Enzymol 1984;105:121-126.
3. Buckman TD, Kling AS, Eiduson S, Sutphin MS, Steinberg A. Glutathione peroxidase and CT scan abnormalities in schizophrenia. Biol Psychiatry 1987;22:349-356.
4. Buckman TD, Kling AS, Eiduson S, Sutphin MS, Steinberg A, Eiduson S. Platelet glutathione peroxidase and monoamine oxidase activity in schizophrenics with CT scan abnormalities: relation to psychosocial variables. Psychiatry Res 1990;31:1-14.
5. Cadet JL, Lohr JB, Jeste DV. Free radicals and tardive dyskinesia. Trends Neurosci 1986;9:107-108.
6. Cadet JL, Lohr JB. Free radicals and the developmental pathology of schizophrenic burnout. Integrative Psychiatry 1987;5:40-48.
7. Cadet JL, Lohr JB. Possible involvement of free radicals in neuroleptic-induced movement disorders. Evidence from treatment of tardive dyskinesia with vitamin E. Ann N Y Acad Sci 1989;570:176-185.
8. Cohen G. Enzymatic/nonenzymatic sources of oxyradicals and regulation of antioxidant defences. Ann N Y Acad Sci 1994;738:8-14.
9. Eddington ND, Young D. Sensitive electrochemical high-performance liquid chromatography assay for the simultaneous determination of haloperidol and reduced haloperidol. J Pharmacol Sci 1988;77:541-543.
10. Glazov VA, Mamzev VP. Catalase in the blood and leucocytes in patients with nuclear schizophrenia. Zh Nevropatol Psikhiatr 1976;4:549-552.
11. Golse B, Debray-Ritzen P, Puget K, Michelson AM. Dosages érythrocytaires et plaquettes des superoxyde dismutases (1 et 2) et de la glutathion peroxydase dans les pychoses infantiles de développement. Nouv Pr Med 1978;7:1952.
12. Golse B, Debray Q, Puget K, Michelson AM. Dosages érythrocytaires de la superoxyde dismutases 1 et de la glutathion peroxydase dans les schizophrénies de l'adulte. Nouv Pr Med 1978;7:2070-2071.
13. Hall SM, Herning RI, Jones RT, Benowitz NL, Jacob III P. Blood cotinine levels as indicators of smoking treatment outcome. Clin Pharmacol Ther 1984;35:810-814.
14. Jarvis MJ, Tunstall-Pedoe H, Feyerabend C, Vesey C, Saloojee Y. Comparison of tests used to distinguish smokers from nonsmokers. Am J Public Health 1987;77:1435-1438.
15. Langone JJ, Gjika HB, van Vunakis H. Nicotine and its metabolites. Radioimmunoassay for nicotine and cotinine. Biochemistry 1973;12:5025-5030.
16. Langone JJ, van Vunakis H, Hill P. Quantitation of cotinine in sera of smokers. Res Commun Chem Pathol Pharmacol 1975;10:21-28.
17. Lohr JB. Oxygen radicals and neuropsychiatric illness: some speculations. Arch Gen Psychiatry 1991;48:1097-1106.
18. Lohr JB, Cadet JL, Lohr MA, Jeste DV, Wyatt RJ. Alpha-tocopherol in tardive dyskinesia. Lancet 1987;I:913-914.
19. Lohr JB, Flynn K. Smoking and schizophrenia. Schizophrenia Res 1992;8:93-102.
20. Lohr JB, Kuczenski R, Bracha HS, Moir M, Jeste DV. Increased indices of free radical activity in the cerebrospinal fluid of patients with tardive dyskinesia. Biol Psychiatry 1990;28:535-539.
21. Mahadik SP, Mukherjee S. Free radical pathology and antioxidant defense in schizophrenia: a review. Schizophrenia Res 1996;19:1-17.
22. Michelson AM, Puget K, Durosay P, Bouneau JC. Clinical aspects of the dosage of erythrocuprein. In: Michelson AM, McCord JM, Fridovich I, editors. Superoxide and Superoxide Dismutase. London: Academic Press, 1977. p. 467-99.
23. Mukherjee S, Mahadik SP, Correnti EE. The antioxidant defense system at the onset of psychosis. Biol Psychiatry 1994;35:701.
24. Ohtsuka Y, Yabunaka N, Fujisawa H, Watanabe I, Agishi Y. Effect of thermal stress on glutathione metabolism in human erythrocytes. Eur J Appl Physiol Occup Physiol 1994;68:87-91.
25. Pickar D, Labarca R, Doran AR, Wolkowitz OM, Roy A, Breier A, Linnoila M, Paul SM. Longitudinal measurement of plasma homovanillic acid in schizophrenic patients: correlation with psychosis and response to neuroleptic treatment. Arch Gen Psychiatry 1986;43:669-676.
26. Pryor WA, Stone K. Oxidants in cigarette smoke: radicals, hydrogen peroxide, peroxynitrate and peroxynitrite. Ann N Y Acad Sci 1993;686:12-27.
27. Reddy R, Mahadik SP, Mukherjee M, Murthy JN. Enzymes of the antioxidant system in chronic schizophrenic patients. Biol Psychiatry 1991;30:409-412.
28. Reddy R, Yao JK. Free radical pathology in schizophrenia: a review. Prostaglandins Leukotriene Essential Fatty Acids 1996;55:33-43.
29. Scarpellini F, Sbracia M, Scarpellini L. Psychological stress and lipoperoxidation in miscarriage. Ann N Y Acad Sci 1994;709:210-213.
30. Sinet PM, Debray Q, Carmagnol F, Pelicier Y, Nicole A, Jerome H. Normal erythrocyte SOD values in two human diseases: schizophrenia and cystic fibrosis. In: Greenwald RA, Cohen G, editors. Oxy-radicals and their Scavenger Systems, vol. II: Cellular and Medical Aspects. New York: Elsevier, 1983. p. 302-4.
31. Smythies JR. Oxidative reactions and schizophrenia: a review-discussion. Schizophrenia Res 1997;24:357-364.
32. Stoklasova A, Zapletalek M, Kudronova K, Randova Z. Glutathione peroxidase activity of blood in chronic schizophrenics. Sbu Ved Praci Lek Fak UK v Hradci Kralove 1985;29 (Suppl.): 103-108.
33. Szabo L, Lajko K, Barabas K, Matkovics B. Effects of neuroleptics on lipid peroxidation and peroxide metabolism enzyme activities in various discrete areas of the rat brain. Chem Pharmacol 1983;14:537-539.
34. van Kammen DP, Kelley ME, Gurklis JA, Gilbertson MW, Yao JK, Condray R, Peters JL. Predicting duration of clinical stability following haloperidol withdrawal in schizophrenia. Neuropsychopharmacology 1996;14:275-283.
35. van Kammen DP, Kelley ME, Gurklis JA, Gilbertson MW, Yao JK, Peters JL. Behavioral vs biochemical prediction of clinical stability following haloperidol withdrawal in schizophrenia. Arch Gen Psychiatry 1995;52:673-678.
36. van Kammen DP, Peters J, van Kammen WB, Nugent A, Goetz KL, Yao J, Linnoila M. Elevated CSF NE and relapse in schizophrenia. Biol Psychiatry 1989;26:178-188.
37. Zapletalk M, Belicova I, Komenda S. Catalase activity in serum of schizophrenics and normals. Cs Psychait 1966;6:401-404.